• EuroBiotech: More Articles of Note fiercebiotech
    May 04, 2018
    Biogen paid Neurimmune $50 million (€42 million) to cut the royalty rate on potential future sales of Alzheimer’s candidate aducanumab by 5%...
PharmaSources Customer Service